A Third-Generation Bisphosphonate, Minodronic Acid (YM529), Augments the Interferon α/β-Mediated Inhibition of Renal Cell Cancer Cell Growth Both In vitro and In vivo

Clinical Cancer Research

Volumn 11, Issue 2, 2005, Pages 853-859

  Yuasa, Takeshi ^a   Nogawa, Masaki ^a   Kimura, Shinya ^a   Yokota, Asumi ^a   Sato, Kiyoshi ^a   Segawa, Hidekazu ^a   Kuroda, Junya ^a   Maekawa, Taira ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; LACTATE DEHYDROGENASE; MINODRONIC ACID; PROTEIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL ASSAY; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LYMPHOCYTE COUNT; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPERNATANT; T LYMPHOCYTE; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; HUMANS; IMIDAZOLES; INTERFERON-ALPHA; INTERFERON-BETA; KIDNEY NEOPLASMS; LUCIFERASES; MICE; RAP1 GTP-BINDING PROTEINS; RAS PROTEINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12244295754     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Novick AC, Campbell SC. Renal tumors. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's urology. New York: Saunders; 2001. p. 2672-731.
3. Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2003; 46: S33–S39.
4. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8.
5. Kuroda J, Kimura S, Segawa H, et al. The third-generation bisphosphonate Zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003; 102: 2229–35.
6. Kimura S, Kuroda J, Segawa H, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines. Int J Hematol 2004; 79: 37-43.
7. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the thirdgeneration bisphosphonate, zoledronate acid alone and combined with anti-cancer agents on small cell lung caner cell lines. Lung Cancer. In press.
8. Nogawa M, Yuasa T, Kimura S, et al. Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Letters. In press.
9. Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 2003; 10: 173-80.
10. Schilbach K, Geiselhart A, Handgretinger R. Induction of proliferation and augmented cytotoxicity of gy T lymphocytes by bisphosphonate clodronate. Blood 2001; 97: 2917–8.
11. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human gy T cells by nonpeptide antigens. J Immunol 2001; 167: 5092-8.
12. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-7.
13. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98: 962-9.
14. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-44.
15. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004; 10: 2584-6.
16. Lara PN Jr, Quinn DI, Margolin K, et al. SU5416 plus interferon a in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 2003; 15: 4772-81.
17. Amato RJ. Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 2003; 46: S59–S65.
18. Fojo AT, Shen DW, Mickley LA, Pastan I, Gottesman MM. Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 1987; 5: 1922-7.
19. Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 2003; 122: 202-10.
20. Berenson J, Ravera C, Ma P, et al. Population pharmacokinetics of zometa [abstract]. Proc ASCO 2000; 209a.
21. Tassone P, Tagliaferri P, Viscomi C, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88: 1971-8.
22. Tassone P, Tagliaferri P, Viscomi C, et al. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience). Acta Pol Pharm 2002; 59: 478-82.
23. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68.
24. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042–57.
25. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42: 1228-36.
26. FDA approves ZOMETA for treatment of cancer-related bone complications. Expert Rev Anticancer Ther 2002; 2: 137–8.